Hepatitis B vaccination targeted at behavioural risk groups in the Netherlands: Does it work?
| Autor: | Irene K. Veldhuijzen, R. van Houdt, Femke D. H. Koedijk, Q. Waldhober, R. A. Coutinho, E L M Op de Coul, R.A. de Man, Jan Hendrik Richardus, G. J. J. Van Doornum, Sylvia M. Bruisten, M.L.A. Heijnen, M. Schutten, Hein J. Boot, Susan Hahné |
|---|---|
| Přispěvatelé: | Amsterdam institute for Infection and Immunity, Medical Microbiology and Infection Prevention, Infectious diseases, Public Health, Virology, Gastroenterology & Hepatology |
| Jazyk: | angličtina |
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male Hepatitis B virus Genotype Population medicine.disease_cause SDG 3 - Good Health and Well-being medicine Humans Hepatitis B Vaccines Hepatitis B Antibodies education Netherlands education.field_of_study General Veterinary General Immunology and Microbiology Immunization Programs business.industry Transmission (medicine) Vaccination Public Health Environmental and Occupational Health Middle Aged Hepatitis B medicine.disease Hepatitis B Core Antigens Sexual intercourse Infectious Diseases Immunization Immunology Molecular Medicine Female Viral disease business Demography |
| Zdroj: | Vaccine, 27(27), 3530-3535. Elsevier BV Vaccine, 27(27), 3530-3535. Elsevier |
| ISSN: | 0264-410X |
| Popis: | In November 2002, the Netherlands adopted a vaccination program targeted at behavioural risk groups. Between January 2003 and December 2007, 1386 patients acutely infected with HBV were reported. Reported cases declined from 326 in 2003 to 220 in 2007. Sexual intercourse was the most frequently reported mode of transmission (65%), especially among men having sex with men. Genotypes A and D remained predominant. In total, 40,600 participants were fully vaccinated, the overall compliance was 62%, and the estimated overall program coverage was 12% of the at-risk population. With more effort, more susceptibles may be reached, but the program will not be sufficient to substantially reduce HBV in the Netherlands. Therefore, universal vaccination should be considered. (C) 2009 Elsevier Ltd. All rights reserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect